Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice

Journal of Clinical Investigation

Volumn 100, Issue 3, 1997, Pages 558-564

  Boonmark, Nataya W ^a   Lou, Xing Jian ^a   Yang, Zhuoying J ^a   Schwartz, Karen ^a   Zhang, Jun Li ^b   Rubin, Edward M ^b   Lawn, Richard M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoprotein; Fibrin; Lipoprotein; Lipoprotein(a); Mouse

Indexed keywords

APOLIPOPROTEIN A1; FIBRIN; LIPOPROTEIN A; LYSINE;

ANIMAL MODEL; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING SITE; CONTROLLED STUDY; FEMALE; GENE MUTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

EID: 1842338654     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119565     Document Type: Article

References (55)

1. Bostom, A.G., L.A. Cupples, J.L. Jenner, J.M. Ordovas, L.L. Seman, P.W.F. Wilson, EJ. Schaefer, and W.P. Castelli. 1996. Elevated plasma lipoprotein(a) and premature coronary heart disease in Framingham men: a prospective study. JAMA (J. Am. Med. Assoc.). 276:544-548.
2. Assmann, G., H. Schulte, and A.V. Eckardstein. 1996. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 77:1179-1184.
3. McLean, J.W., J.E. Tomlinson, W.J. Kuang, D.L. Eaton, E.Y. Chen, G.M. Fless, A.M. Scanu, and R.M. Lawn. 1987. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature (Lond.). 330:132-137.
4. Scanu, A.M., and G.M. Fless. 1990. Lipoprotein(a): heterogeneity and biological relevance. J. Clin. Invest. 85:1709-1715.
5. Utermann, G. 1989. The mysteries of lipoprotein(a). Science (Wash. DC). 246:904-910.
6. Miles, L.A., and E.F. Plow. 1990. Lp(a): an interloper into the fibrinolytic system? Thromb. Haemost. 63:331-335.
7. Harpel, P.C., B.R. Gordon, and T.S. Parker. 1989. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc. Natl. Acad. Sci. USA. 86:3847-3851.
8. Miles, L.A., G.M. Fless, E.G. Levin, A.M. Scanu, and E.F. Plow. 1989. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature (Lond.). 339:301-303.
9. Hajjar, K.A., D. Gavish, J.L. Breslow, and R.L. Nachman. 1989. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature (Lond.). 339:303-305.
10. Edelberg, J.M., M. Gonzalez-Gronow, and S.V. Pizzo. 1990. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb. Res. 57:155-162.
11. Loscalzo, J., M. Weinfeld, G.M. Fless, and A.M. Scanu. 1990. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 10:240-245.
12. Gonzalez-Gronow, M., J.M. Edelberg, and S.V. Pizzo. 1989. Further characterization of the cellular plasminogen binding site: evidence that plasminogen and lipoprotein(a) compete for the same site. Biochemistry. 28:2374-2377.
13. Rouy, D., P. Grailhe, F. Nigon, J. Chapman, and E. Angles-Cano. 1991. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler. Thromb. 11: 629-638.
14. Leerink, C., P. Duif, J. Gimpel, W. Kortlandt, B.N. Bouma, and H. von Rijn. 1992. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation. Thromb. Haemost. 68:185-188.
15. Grainger, D.J., H.L. Kirschenlohr, J.C. Metcalfe, P.L. Weissberg, D.P. Wade, and R.M. Lawn. 1993. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science (Wash. DC). 260:1655-1658.
16. Kojima, S., P.C. Harpel, and D.B. Rifkin. 1991. Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 113:1439-1445.
17. Williams, J.K., D.A. Bellinger, T.C. Nichols, T.R. Griggs, T.F. Bumol, R.L. Fouts, and T.B. Clarkson. 1993. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler. Thromb. 113:548-554.
18. Moliterno, D.J., R.A. Lange, R.S. Meidell, J.E. Willard, C.C. Leffert, R.D. Gerard, E. Boerwinkle, H.H. Hobbs, and L.D. Hillis. 1993. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation. 88:935-940.
19. Grainger, D.J., P.R. Kemp, J.C. Metcalfe, A.C. Liu, R.M. Lawn, N.R. Williams, A.A. Grace, P.M. Schofield, and A. Chauhan. 1995. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat. Med. 1:74-79.
20. Palabrica, T.M., A.C. Liu, M.J. Aronovitz, B. Furie, R.M. Lawn, and B.C. Furie. 1995. Human apolipoprotein(a) transgenic mice are resistant to thrombolysis. Nat. Med. 1:256-259.
21. Grainger, D.J., P.R. Kemp, A.C. Liu, R.M. Lawn, and J.C. Metcalfe. 1994. Activation of transforming growth factor-β is inhibited in apolipoprotein(a) transgenic mice. Nature (Lond.). 370:460-462.
22. Lawn, R.M., D.P. Wade, R.E. Hammer, G. Chiesa, J.G. Verstuyft, and E.M. Rubin. 1992. Atherogenesis in transgenic mice expressing human apoliprotein(a). Nature (Lond.). 360:670-672.
23. Liu, A.C., J.G. Verstuyft, E.M. Rubin, and R.M. Lawn. 1994. Inhibition of atherogenesis in apolipoprotein(a) transgenic mice by the addition of the apolipoprotein AI transgene. J. Lipid Res. 35:2263-2267.
24. Callow, M.J., J. Verstuyft, R. Tangirala, W. Palinski, and E.M. Rubin. 1995. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein(a). J. Clin. Invest. 96:1639-1646.
25. Mancini, F.P., D.L. Newland, V. Mooser, J. Murata, S. Marcovina, S.G. Young, R.E. Hammer, D.A. Sanan, and H.H. Hobbs. 1995. Relative contributions of apolipoprotein(a) and apolipoprotein B to the development of fatty lesions in the proximal aorta of mice. Arterioscler. Thromb. Vasc. Biol. 15:1911-1916.
26. Lawn, R.M., A.D. Pearle, L.L. Kunz, E.M. Rubin, J. Reckless, J.C. Metcalfe, and D.J. Grainger. 1996. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J.Biol. Chem. 271:31367-31371.
27. Mulichak, A.M., A. Tulinsky, and K.G. Ravichandran. 1991. Crystal and molecular structure of human plasminogen kringle 4 refined at 1.9 Å resolutions. Biochemistry. 30:10576-10588.
28. Wu, T.P., K. Padmanabhan, A. Tulinsky, and A.M. Mulichak. 1991. The refined structure of the ε-aminocaproic acid complex of human plasminogen kringle 4. Biochemistry. 30:10589-10594.
29. Nielsen, P.R., K. Einer-Jensen, T.L. Holtet, B.D. Andersen, F.M. Poulsen, and H.C. Thogersen. 1993. Protein-ligand interactions in the lysine-binding site of plasminogen kringle 4 are different in crystal and solution. Electrostatic interactions studies by site-directed mutagenesis exclude lys35 as an important acceptor in solution. Biochemistry. 32:13019-13025.
30. McCance, S.G., N. Menhart, and F.J. Castellino. 1994. Amino acid residues of the kringle-4 and kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands. J. Biol. Chem. 269:32405-32410.
31. Guervara, J., Jr., A.Y. Jan, R. Knapp, A. Tulinsky, and J.D. Morrisett. 1993. Comparison of ligand-binding sites of modeled apo(a) kringle-like sequences in human lipoprotein(a). Arterioscler. Thromb. 13:758-770.
32. Scanu, A.M., D. Pfaffinger, J.C. Lee, and J. Hinman. 1994. A single point mutation (Trp72 →Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim. Biophys. Acta. 1227:41-45.
33. Scanu, A.M. 1995. Identification of mutations in human apolipoprotein(a) kringle 4-37 from the study of the DNA of peripheral blood lymphocytes: relevance to the role of lipoprotein(a) in atherothrombosis. Am. J. Cardiol. 75:588-618.
34. LoGrasso, P.V., S. Cornell-Kennon, and B.R. Boettcher. 1994. Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37. J. Biol. Chem. 269:21820-21827.
35. Ernst, A., M. Helmhold, C. Brunner, A. Petho-Schramm, V.W. Armstrong, and H.J. Müller. 1995. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J. Biol. Chem. 270:6227-6234.
36. Klezovitch, L., and A.M. Scanu. 1996. Lys and fibrinogen binding of wild-type (trp72) and mutant (Arg72) human apo(a) kringle IV-10 expressed in e. coli and CHO cells. Arterioscler. Thromb. Vasc. Biol. 16:392-398.
37. Hoover-Plow, J.L., N. Boonmark, P. Skocir, R. Lawn, and E.F. Plow. 1996. A quantitative immunoassay for the lysine-binding function of lipoprotein(a): Application to recombinant apo(a) and lipoprotein(a) in plasma. Arterioscler. Thromb. Vasc. Biol. 16:656-664.
38. Harpel, P.C., V.T. Chang, and W. Borth. 1992. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc. Natl. Acad. Sci. USA. 89:10193-10197.
39. Widom, R.L, J.A. Ladias, S. Kouidou, and S.K. Karathanasis. 1991. Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells. Mol. Cell. Biol. 11:677-687.
40. Mortimer, B.-C., T.G. Redgrave, E.A. Spangler, J.G. Verstuyft, and E.M. Rubin. 1994. Effect of human ApoE4 on the clearance of chylomicron-like lipid emulsions and atherogenesis in transgenic mice. Arterioscler. Thromb. 14:1542-1552.
41. Rubin, E.M., R. Krauss, E. Spangler, S. Verstuyft, and S. Clift. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature (Lond.). 353:265-267.
42. Snedecor, G.W., and W.G. Cochran. 1972. Statistical Methods. University of Iowa Press, Iowa City, IA. 111-114.
43. Mosedale, D.E., J.C. Metcalfe, and D.J. Grainger. 1996. Optimization of immunofluorescence methods by quantitative image analysis. J. Histochem. Cytochem. 44:1043-1050.
44. Winn, E.S., S.P. Hu, S.M. Hochschwender, and R.A. Laursen. 1980. Studies on the lysine-binding sites of human plasminogen: the effect of ligand structure on the binding of lysine analogs to plasminogen. Eur. J. Biochem. 104: 579-586.
45. Lackner, C., J.C. Cohen, and H.H. Hobbs. 1993. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum. Mol. Genet. 2:933-940.
46. van der Hoek, Y.Y., M.E. Wittekoek, U. Beisiegel, J.J. Kastelein, and M.L. Koschinsky. 1993. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum. Mol. Genet. 2:361-366.
47. Klezovitch, O., C. Edelstein, and A.M. Scanu. 1996. Evidence that fibrinogen binding domain of apo(a) is outside the lysine binding site of kringle IV-10. J. Clin. Invest. 98:185-191.
48. Chiesa, G., H.H. Hobbs, M.L. Koschinsky, R.M. Lawn, S.D. Maika, and R.E. Hammer. 1992. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J. Biol. Chem. 267:24369-24374.
49. Knight, B.L., N.Y.F. Perombelon, A.K. Soutar, D.P. Wade, and M. Seed. 1991. Catabolism of lipoprotein (a) in familial hypercholesterolemic subjects. Atherosclerosis. 87:227-237.
50. Rader, D.J., W.A. Mann, W. Cain, H.G. Kraft, D. Usher, and L.A. Zech. 1995. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J. Clin. Invest. 95:1403-1408.
51. Bader, G., C. Edelstein, R.D. Samburek, M. Nishiwaki, H. Nazih, C. Schwartz, A.M. Scanu, and H.B. Brewer, Jr. 1996. Lp(a): comparison of the in vivo metabolism of apo(a) and Lp(a) in man. Circulation. 94(Suppl.):1-39.
52. Trieu, V.N., T.F. Zioncheck, R.M. Lawn, and W.J. McConathy. 1991. Interaction of apolipoprotein(a) with apolipoprotein B-containing lipoproteins. J. Biol. Chem. 266:5480-5485.
53. Linton, M.F., R.V. Farese, G. Chiesa, D.S. Grass, P. Chin, R.E. Hammer, H.H. Hobbs, and S.G. Young. 1993. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92:3029-3037.
54. Callow, M., L. Stoltzfus, R.M. Lawn, and E.M. Rubin. 1994. Expression of human apolipoprotein B and assembly of lipoprotein (a) in transgenic mice. Proc. Natl. Acad. Sci. USA. 91:2130-2134.
55. Armstrong, V.W., B. Harrach, H. Robenek, M. Helmhold, A.K. Walli, and D. Seidel. 1990. Heterogeneity of human lipoprotein Lp(a): cytochemical and biochemical studies of the interaction of two Lp(a) species with the LDL receptor. J. Lipid Res. 31:429-441.